Lonza Licenses Gene Expression Technology to Sorrento

The biopharmaceutical company Sorrento Therapeutics and Lonza have formed a nonexclusive research license agreement, under which Sorrento gains access to Lonza’s GS Xceed Gene Expression System. The GS Xceed System is used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio.

The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of therapeutic antibodies in oncology, inflammation, and infectious disease. Sorrento has shown yields of up to 3g/L with the GS Xceed System, in the production of antibodies targeting the vascular epidermal growth factor receptor 2 (VEGFR2), an important anti-angiogenesis target for a number of solid tumor indications. Several monoclonal antibodies (mAbs) will be produced and developed under the new agreement, including Sorrento’s lead anti-PD-L1 and anti-PD-1 antibodies, as well as a selection of traditionally difficult-to-obtain anti-chemokine receptor mAbs.

Source:

Lonza